An Early Phase 1 interventional study of lidocaine 2.5%/prilocaine 2.5% topical anesthetic and lidocaine 7%/tetracaine 7% topical anesthetic in Lentigo, sponsored by Northwestern University. Completed at 1 site in United States. Open to female participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Northwestern University · Early Phase 1, Interventional, and Other
This study will conduct a split-face and -body randomized control trial to compare lidocaine 2.5%/prilocaine 2.5% topical anesthetic (LPTA), lidocaine 7%/tetracaine 7% topical anesthetic (LTTA), and placebo vechicle (PV) on patients' pain perceptions with Q-switched 532nm laser for the treatment of lentigines and/or photorejuvenation.Subjects will fill out a pain score on a visual analog scale (VAS) with 0 being no pain and 10 being most pain after each treatment area is completed.
Exclusion Criteria:
Has received the following treatments on the face:
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
Drug: lidocaine 2.5%/prilocaine 2.5% topical anesthetic · Device: Q-switched 532nm Laser
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
Drug: lidocaine 7%/tetracaine 7% topical anesthetic · Device: Q-switched 532nm Laser
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
Drug: placebo vehicle · Device: Q-switched 532nm Laser
visual analog score (VAS) pain rating
Subjects will fill out a visual analog score (VAS) pain rating after treatment with 0 being no pain and 10 being worst pain
Time frame: Day of treatment
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Northwestern University